Ut Health San Antonio Mays Cancer Center

San Antonio, Texas 78229-4427

2 studies enrolling now · 14 studies all time

What they study most

Advanced Solid Tumor, Advanced Solid Tumors, Breast Cancer, Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma, Fallopian Tube Cancer, Glioblastoma, Glioblastoma Multiforme, HNSCC for Phase 2 Dose Expansion, Hepatocellular Carcinoma (HCC), Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, Meningioma, Metastatic Breast Cancer

Studies at this site

• A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors — Recruiting now
• A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma — Recruiting now
• A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors — Recruiting now
• A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer — Running, not enrolling
• BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors — Completed
• An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) — Running, not enrolling
• ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study — Running, not enrolling
• Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors — Completed
• A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB) — Running, not enrolling
• A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC) — Completed
• Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer — Completed
• A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors — Stopped early
• Demonstration of a Novel Approach Using Surface-Image Guidance to Improve Delivery of Breast Radiotherapy — Completed
• A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat — Completed